CytoSorbents Corp (STU:HQE1)
€ 0.75 -0.003 (-0.4%) Market Cap: 45.66 Mil Enterprise Value: 53.99 Mil PE Ratio: 0 PB Ratio: 2.60 GF Score: 66/100

Cytosorbents Corp at UBS Global Healthcare Virtual Conference Transcript

May 26, 2021 / 07:00PM GMT
Release Date Price: €6.61 (+0.15%)
Tim Peters

Good afternoon. Thank you for coming to the 2021 Virtual UBS Global Healthcare Conference. My name is Tim. I'm happy to be your host for this session. Our next presenter will be Dr. Phillip Chan from CytoSorbents. Q&A session will follow immediately after the presentation. (Operator Instructions)

We now turn it over to Dr. Chan. Thank you.

Phillip P. Chan
Cytosorbents Corporation - CEO & Director

Thank you very much, Tim, and thank you very much for the invitation to be here today. It's a pleasure to introduce the CytoSorbents story to new investors. If you can follow along with the presentation, let's go Slide 2. As a publicly traded company, please let me remind you of our safe harbor statement for forward-looking statements.

On Slide 3. CytoSorbents is leading the prevention or treatment of life-threatening inflammation, cytokine storm and other deadly conditions in the ICU and cardiac surgery using our CytoSorb blood purification technology.

On the next slide. CytoSorbents is a rapidly growing, international,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot